TY - JOUR T1 - Spread of COVID-19 through Georgia, USA. Near-term projections and impacts of social distancing via a metapopulation model JF - medRxiv DO - 10.1101/2020.05.28.20115642 SP - 2020.05.28.20115642 AU - Stephen J. Beckett AU - Marian Dominguez-Mirazo AU - Seolha Lee AU - Clio Andris AU - Joshua S. Weitz Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/30/2020.05.28.20115642.abstract N2 - Epidemiological forecasts of COVID-19 spread at the country and/or state level have helped shape public health interventions. However, such models leave a scale-gap between the spatial resolution of actionable information (i.e. the county or city level) and that of modeled viral spread. States and nations are not spatially homogeneous and different areas may vary in disease risk and severity. For example, COVID-19 has age-stratified risk. Similarly, ICU units, PPE and other vital equipment are not equally distributed within states. Here, we implement a county-level epidemiological framework to assess and forecast COVID-19 spread through Georgia, where 1,933 people have died from COVID-19 and 44,638 cases have been documented as of May 27, 2020. We find that county-level forecasts trained on heterogeneity due to clustered events can continue to predict epidemic spread over multiweek periods, potentially serving efforts to prepare medical resources, manage supply chains, and develop targeted public health interventions. We find that the premature removal of physical (social) distancing could lead to rapid increases in cases or the emergence of sustained plateaus of elevated fatalities.HighlightsContact heterogeneity and age-structured risk is represented in a metapopulation model.The metapopulation model can be used in the near-term to make joint predictions on cases, hospitalizations, and fatalities at county levels.In Georgia, a long-term plateauing epidemic, rather than a distinctive epidemic peak, is possible.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch effort by JSW and co-authors at the Georgia Institute of Technology was enabled by support from grants from the Simons Foundation (SCOPE Award ID 329108), the Army Research Office (W911NF1910384), National Institutes of Health (1R01AI46592-01), and National Science Foundation (1806606 and 1829636). Funding sources had no role or influence on study design, analysis, interpretation, or submission.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll simulation and codes used in the development of this manuscript are available at https://github.com/WeitzGroup/MAGEmodel_covid19_GA/ https://github.com/WeitzGroup/MAGEmodel_covid19_GA/ ER -